CliffBio
biologic

Pertzye

pancrelipase

Loss of exclusivityJuly 2029projected — 12-year biologic exclusivity estimate
CompanyDigestive Care, Inc. →View the full company profile on CliffBio

Drug detail

Brand namePertzye
Active ingredientpancrelipase
Strength24,000USP UNITS; 86,250USP UNITS; 90,750USP UNITS
Dosage formCapsule, Delayed Release
RouteOral
ModalityBiologic
FDA approvalJuly 2017
Marketing statusRx

More from Digestive Care, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Not found